Formlabs, University of South Florida Health, Northwell Health and Tampa General Hospital joined forces to create 3D printed nasal swabs to test for COVID-19 in patients in emergency shortage situations.
In addition, the FDA granted Formlabs emergency clearance for 3D-printed ventilator component.
GreenLight Biosciences is expanding their vaccine efforts to establish a scalable current Good Manufacturing Practices (cGMP) manufacturing platform to allow for the production of almost any RNA-based COVID-19 vaccine at a scale and cost that enables global delivery. In addition, they are advancing a number of RNA-based vaccines and therapeutics against COVID-19.
Eli Lilly and Co. reached an agreement with the National Institutes of Health to study one of its drugs as a COVID-19 treatment. The drug is approved in more than 65 countries as a treatment for adults with moderately to severely active rheumatoid arthritis.
They also opened labs and planned drive-thrus to help boost Indiana's COVID-19 testing capacity.
Kaleido Biosciences has initiated a controlled clinical study of Microbiome Metabolic Therapy KB109 in outpatients with mild-to-moderate COVID-19.
Since then, Kaleido Biosciences has initiated a controlled clinical study with Mass General Hospital of Microbiome Metabolic Therapy KB109 in outpatients with mild-to-moderate COVID-19.
After starting human trials for a COVID-19 vaccine, Moderna was featured on 60 minutes.
Since then, their potential coronavirus vaccine got $483 million boost from Feds.
Moderna announced positive interim Phase 1 data for its mRNA vaccine (mRNA-1273) against novel coronavirus.
Moderna, the first company to start US clinical trials of a Covid-19 vaccine, finished enrolling all 30,000 of its participants.
NOBULL is donating thousands of CDC recommended face masks to medical professionals. They were able to access the masks from an FDA registered factory through their partners. They are accepting donations to procure face masks or other PPE for medical professionals.
BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), will accept an Indefinite Delivery Indefinite Quantity (IDIQ) contract award to provide Commercial Surge Capacity Testing for COVID-19 Emergency Response to the Centers for Disease Control and Prevention (CDC).
Pfizer and BioNTech are co-developing a potential COVID-19 vaccine.
Pfizer and the Pfizer Foundation have also announced the commitment of $40 million in medical and charitable cash grants to help combat the global health effects of the COVID-19 pandemic in the US and around the world.
Researchers across the globe are deploying Quanterix Corporation’s Simoa® technology to profile innate immune response in COVID-19 patients, with the aim of identifying indicators associated with poor outcomes and opening new avenues for targeted therapies.
The sweeping impacts of COVID-19 are immeasurable and, at times, defeating. We have taken solace in the fact that people across the globe are coming together (while remaining socially distant) to help address and overcome this pandemic. As a firm, we feel incredibly fortunate to support clients across industries and geographies–some of whom were part of the earliest adopters in shifting gears and focusing on efforts to combat coronavirus.
During this unprecedented time, we want you to know that we are still here to help. We vow to provide you with the high level of service you deserve, and we will do everything we can to have a positive impact on you. We want our clients to be able to focus on their families and know their IP interests are safe with us.
Our sincere thoughts are with those impacted by the virus.
Mechanical Technologies Chair
Electrical Computer Technologies Chair
Chemical & Material Technologies Chair
Trademark & Copyright Chair